Infections In Patients with Kidney Disease -
Dialysis - Hemodialysis - ESRD
Infections in Hemodialysis Dialysis End Stage Renal Failure Patients
Updated Dec 20 2012
Hemodialysis.com Author Interview: Shree G Sharma, M.D.
Shree G. Sharma, Volker Nickeleit, Leal C. Herlitz, Anne K. de Gonzalez, Michael B. Stokes, Harsharan K. Singh, Glen S. Markowitz, and Vivette D. D'Agati
Nephrol. Dial. Transplant. first published online December 18, 2012 doi:10.1093/ndt/gfs537
|
|
|
|
Hemodialysis.com Author Interview: Shih-Yi Lin
|
|
Hemodialysis.com Author Interview: Chukwuma Mbaeyi BDS (DDS), MPH
Assessment of Management Policies and Practices for Occupational Exposure to Bloodborne Pathogens in Dialysis Facilities
Mbaeyi C, Panlilio AL, Hobbs C, Patel PR, Kuhar DT.
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA.
Am J Kidney Dis. 2012 Jun 26. [Epub ahead of print]
|
Hemodialysis.com Author Interview: Gagangeet Sandhu MD
Effect of Aggressively Driven Intravenous Iron Therapy on Infectious Complications in End-Stage Renal Disease Patients on Maintenance Hemodialysis
Bansal, Anip MD; Sandhu, Gagangeet MD; Gupta, Isha MD; Kalahalli, Shriharsha MD; Nayak, Rushi MD; Zouain, Eduardo MD; Chitale, Rohit A PhD, MPH; Meisels, Ira MD; Chan, Germaine MD
POST AUTHOR CORRECTIONS, 23 July 2012
doi: 10.1097/MJT.0b013e31825425bd
|
Author Interview Dr. AM Onder
Antibiotic lock solutions allow less systemic antibiotic exposure and less catheter malfunction without adversely affecting antimicrobial resistance patterns.
Onder, A. M., Billings, A. A., Chandar, J., Nield, L., Francoeur, D., Simon, N., Abitbol, C. and Zilleruelo, G. (2012), Hemodialysis International. doi: 10.1111/j.1542-4758.2012.00717.x
|
Perit Dial Int pdi.2011.00268; published ahead of print June 1, 2012
doi:10.3747/pdi.2011.00268
|
Am J Kidney Dis. 2012 May 8. [Epub ahead of print]
Wu MY, Hsu YH, Su CL, Lin YF, Lin HW.
Department of Nephrology, Shuang Ho Hospital,
Taipei Medical University, Taipei, Taiwan.
|
Authors: Sarah H. Yi, Alexander J. Kallen, John A. Jernigan, Priti R. Patel
for the members of the CDC Dialysis BSI Prevention Collaborative
Affiliation: Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA USA
Presented at National Kidney Foundation Spring Clinical Meeting 2012
|
John J. Dixon, Maggi Steele and A. David Makanjuola
Nephrol. Dial. Transplant. first published online April 18, 2012 doi:10.1093/ndt/gfs081
|
Silva J, Antunes J, Carvalho T, Ponce P.
Hemodial Int. 2012 Apr 20. doi: 10.1111/j.1542-4758.2012.00691.x.
[Epub ahead of print]
Department of Hemodialysis, Nephrocare Grândola, Grândola, Portugal.
|
Authors' Interview:
M. Alan Brookhart, PhD and Leah McGrath, MHS
Influenza Vaccine Effectiveness in Patients on Hemodialysis
An Analysis of a Natural Experiment
Leah J. McGrath, MHS; Abhijit V. Kshirsagar, MD, MPH; Stephen R. Cole, PhD; Lily Wang, PhD;David J. Weber, MD, MPH; Til Stürmer, MD, MPH; M. Alan Brookhart, PhD
Arch Intern Med. 2012;172(7):548-554. doi:10.1001/archinternmed.2011.2238
|
BERKELEY, CA, Mar 27, 2012 (MARKETWIRE via COMTEX) -- Dynavax Technologies Corporation today announced final data from a pivotal Phase 3 trial in patients with chronic kidney disease (CKD) demonstrating early seroprotection and the durability of the immune response to HEPLISAV compared to Engerix-B(R). In October 2011, Dynavax reported that the superiority endpoint had been met in this trial. The trial included 516 patients 18-75 years of age with CKD (stage 3b or higher) in the U.S., Canada and Germany who received 3 doses of HEPLISAV at 0, 1 and 6 months or 4 double doses of Engerix-B at 0, 1, 2 and 6 months (8 doses total).
|
Download the full PDF including tables
March 16, 2012 / 61(10);169-173
Patients undergoing hemodialysis are at risk for bloodstream infections (BSIs), and preventing these infections in this high-risk population is a national priority (1). During 2008, an estimated 37,000 BSIs related to central lines occurred among hemodialysis patients in the United States. This is almost as many as the estimated 41,000 central line–associated BSIs that occurred during 2009 among patients in critical-care units and wards of acute-care hospitals. In 2009, to decrease BSI incidence in a New Jersey outpatient hemodialysis center, a package of interventions was instituted, beginning with participation in a national collaborative BSI prevention program and augmented by a social and behavioral change process to enlist staff members in infection prevention.
Rates of BSIs related to the patient's vascular access (i.e., access-related BSIs [ARBs]) were evaluated in the preintervention and postintervention periods. The incidence of all ARBs decreased from 2.04 per 100 patient-months preintervention to 0.75 (p=0.03) after initiating program interventions and to 0.24 (p<0.01) after adding a behavioral change intervention. Only one ARB occurred during the last 12 postintervention months. At this hemodialysis facility, participating in a collaborative prevention program along with implementation of a behavioral change strategy was associated with a large decrease in ARBs. Other outpatient hemodialysis facilities also might reduce ARBs by adopting similar approaches to prevention.
|
ASN 2011 Abstract Authors' Interview:
Outcomes from a Multi-Center Catheter Reduction Collaborative Program.
Alex Rosenblum, RN, CNN, Eduardo Lacson, Jr., MD, MPH, Jill Hall, RN, CNN, Shu-Fang Lin, MA, Raymond Hakim, MD, PhD. Fresenius Medical Care, Waltham, MA.
|
|
Author Interview: Dr. Mira T Keddis MD
Clinical Outcomes of Clostridium difficile Infection in Patients with Chronic Kidney Disease
ASN 2011 Abstract: [TH-PO248]
Mira T. Keddis, MD, Sahil Khanna, MBBS, Larry M. Baddour, MD, Darell S. Pardi, MD, Qi Qian, MD. Nephrology, Mayo Clinic, Rochester, MN; Gastroenterology, Mayo Clinic, Rochester, MN; Infectious Diseases, Mayo Clinic, Rochester, MN. |
Patel G, Jenkins SG, Mediavilla JR, Kreiswirth BN, Radbill B, Salgado CD, Calfee DP.
Department of Medicine, Mount Sinai School of Medicine, New York, New York.
Infect Control Hosp Epidemiol. 2011 Sep;32(9):881-8.
|
Author Interview: Cheng-Chia Lee, MD
Comparable ten-year outcome in hemodialysis patients with hepatitis C virus and hepatitis B virus coinfection and single hepatitis B virus infection.
Lee CC, Li IJ, Chen YC, Cheng JW, Wu HH, Weng CH, Fang JT, Tian YC.
Department of Nephrology, Lin-Kou Chang Gung Memorial Hospital, Taipei, and Department of Medicine, Chang Gung University, Taiwan, ROC.
Blood Purif. 2011;32(2):89-95.
|
|
|
|
|
|
Nasal Carriage of Methicillin-resistant Staphylococcus aureus Is Associated with Higher All-Cause Mortality in Hemodialysis Patients.
Clin J Am Soc Nephrol. 2011 Jan;6(1):167-74.
Lai CF, Liao CH, Pai MF, Chu FY, Hsu SP, Chen HY, Yang JY, Chiu YL, Peng YS, Chang SC, Hung KY, Tsai TJ, Wu KD.
Department of Internal Medicine, Far Eastern Memorial Hospital, No. 21, Nan-Ya South Road, Ban Ciao City, Taipei, 220, Taiwan
|
Tao JL, Ma J, et al
Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
|
Hemodialysis Vascular Access Type and Bloodstream Infection Rates
Eduardo K. Lacson, Weiling Wang, J. Michael Lazarus, Raymond M. Hakim. Fresenius Medical Care, North America, Waltham, MA
November 19, 2010
Introduction: We evaluated bloodstream infection (BSI) rates based on positive blood cultures by type of vascular access in a national cohort of incident hemodialysis (HD) patients during their first year.
|
Perit Dial Int. 2010 Jul 29.
Williams VR et al
Infection Prevention and Control, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
|
|
Dalrymple LS, et al
Medicine, University of California Davis, Sacramento, CA.
|
|
|
|
|
|
|
